九洲药业：收到枸橼酸坦度螺酮化学原料药上市申请批准通知书

Core Viewpoint - The approval of the citric acid tianeptine raw material drug by the National Medical Products Administration will enhance the company's product portfolio and competitiveness, although it will not have a significant short-term impact on performance [1] Group 1: Product Approval - The company has received the approval notice for the citric acid tianeptine raw material drug from the National Medical Products Administration [1] - The drug is classified as an anti-anxiety medication [1] Group 2: Research and Development Investment - The company submitted the listing application in July 2024 and has invested approximately 6.23 million yuan in research and development [1] Group 3: Market Potential - The global market sales for the drug are projected to reach 390 million USD in 2024 and 750 million USD by 2031 [1] Group 4: Impact on Company Performance - The approval will enrich the company's product structure and enhance competitiveness, but it is noted that there will be no significant short-term impact on performance [1] - There are uncertainties associated with drug production and sales [1]